Skip to main content
All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for AMGEN · Biotechnology.

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2025 · California · House · Senate · $60,000.00 income · posted Apr 21, 2025

Official filing document

 Bills named in this filing 2
  • HR 1968
    Full-Year Continuing Appropriations and Extensions Act, 2025
  • HR 1990
    American Innovation and R&D Competitiveness Act of 2025
 Lobbying activity 4
Medicare/Medicaid

Monitored implementation of P.L. 117-169, the Inflation Reduction Act as it relates to drug pricing. Issues related to biosimilars. Monitored issues related to cardiovascular health. Issues related to pharmacy benefit management. Monitored issues related to dialysis services. H.R. 1968 (P.L. 119-4), Full-Year Continuing Appropriations and Extensions Act, 2025.

Health Issues

Issues related to pharmacy benefit management. Issues related to cardiovascular care. Issues related to drug pricing. H.R. 1968 (P.L. 119-4), Full-Year Continuing Appropriations and Extensions Act, 2025.

Copyright/Patent/Trademark

Monitored issues related to intellectual property.

Taxation/Internal Revenue Code

H.R. 1990, the American Innovation and R&D Competitiveness Act, as it relates to the R&D tax credit. Issues related to the extension of the 2017 Tax Cut and Jobs Act, and corporate taxes.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem